ClinicalTrials.gg

Program

ripretinib

Also written as “Ripretinib” and “DCC-2618”.

Its studies are mostly in Gastrointestinal Stromal Tumors, led by 2 companies.

Furthest: phase 3, since Nov 20, 20179 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ono Pharmaceutical73 open or runningphase 3since Nov 20, 2017Oct 5, 2015Dec 2027phase 3 · NCT05734105
Zai Lab20 open or runningphase 2since Feb 21, 2020Feb 21, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 5, 2015First study: phase 1 study in Gastrointestinal Stromal TumorsNew to Ono PharmaceuticalOno Pharmaceutical · NCT02571036 · 282 enrolled · United States, Canada, Germany and more
  2. Nov 20, 2017Phase 3 study in Gastrointestinal Stromal TumorsOno Pharmaceutical · NCT03353753 · 129 enrolled · United States, Australia, Belgium and more
  3. Sep 13, 2018Phase 3 study in Gastrointestinal Stromal TumorsOno Pharmaceutical · NCT03673501 · 453 enrolled · United States, Argentina, Australia and more
  4. Feb 21, 2020Zai Lab's first study: phase 2 study in Gastrointestinal Stromal TumorsNew to Zai LabZai Lab · NCT04282980 · 39 enrolled · China
  5. Aug 24, 2020Phase 1 study in Gastrointestinal Stromal TumorsOno Pharmaceutical · NCT04530981 · 13 enrolled · United States
  6. Nov 11, 2020Phase 2 study in Gastrointestinal Stromal TumorsZai Lab · NCT04633122 · 108 enrolled · China
  7. Sep 20, 2021Phase 2 study in Gastrointestinal Stromal TumorsOno Pharmaceutical · NCT05080621
  8. Feb 8, 2023Phase 3 study in Gastrointestinal Stromal TumorsOno Pharmaceutical · NCT05734105 · 54 enrolled · United States, Australia, Brazil and more
  9. May 25, 2026Phase 1 study in Gastrointestinal Stromal TumorsOno Pharmaceutical · NCT07618377 · 10 planned · Japan

Ahead

  1. Dec 2027Primary completion: phase 3 study in Gastrointestinal Stromal TumorsOno Pharmaceutical · NCT05734105
  2. Feb 2028Primary completion: phase 1 study in Gastrointestinal Stromal TumorsOno Pharmaceutical · NCT07618377

TargetBeta

KIT →PDGFRA →read by rule
“An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), ”NCIt, by rule
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07618377Gastrointestinal Stromal Tumors · Japan1RecruitingOno PharmaceuticalFeb 202810
NCT05734105Gastrointestinal Stromal Tumors · United States, Australia, Brazil and more3Active, not recruitingOno PharmaceuticalDec 202754
NCT05080621Gastrointestinal Stromal Tumors2WithdrawnOno PharmaceuticalNov 20250
NCT04633122Gastrointestinal Stromal Tumors · China2CompletedZai LabJul 20, 2022108
NCT04530981Gastrointestinal Stromal Tumors · United States1CompletedOno PharmaceuticalNov 16, 202313
NCT04282980Gastrointestinal Stromal Tumors · China2CompletedZai LabFeb 26, 202139
NCT03673501Gastrointestinal Stromal Tumors · United States, Argentina, Australia and more3Active, not recruitingOno PharmaceuticalSep 1, 2021453
NCT03353753Gastrointestinal Stromal Tumors · United States, Australia, Belgium and more3CompletedOno PharmaceuticalMay 31, 2019129
NCT02571036Gastrointestinal Stromal Tumors · United States, Canada, Germany and more1CompletedOno PharmaceuticalApr 29, 2022282

How it is read

Names in the registry

  • “Ripretinib”, 5 entries
  • “DCC-2618”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.